Joohyeon Kim
Overview
Explore the profile of Joohyeon Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
7
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khaliq N, Amin L, Khaliq S, Amin A, Omer S, Khaliq I, et al.
ACS Appl Bio Mater
. 2024 Nov;
7(12):8163-8176.
PMID: 39601471
Peptide-based prodrugs, such as peptide-drug conjugates (PDCs), are currently being developed for cancer therapy. PDCs are considered single-component nanomedicines with various functionalities. The peptide moieties provide stability to the PDCs,...
2.
Khaliq N, Lee J, Kim Y, Kim J, Kim T, Yu S, et al.
Biochim Biophys Acta Gen Subj
. 2024 Aug;
1868(11):130703.
PMID: 39163944
Background: Immunotherapy is a powerful strategy for treating cancer and can be used to inhibit the post-surgical relapse of tumors. Methods: To achieve this, a Cell@hydrogel was developed as a...
3.
Khaliq N, Lee J, Kim J, Kim Y, Yu S, Kim J, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242674
Cancer remains a major global health challenge. Traditional chemotherapy often results in side effects and drug resistance, necessitating the development of alternative treatment strategies such as gene therapy. Mesoporous silica...
4.
Shinn J, Lee J, Lee S, Lee S, Choi A, Kim J, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145716
RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including...